title: Salivary and gastric epidermal growth factor in patients with Zollinger-Ellison syndrome: its protective potential.
abstract: OBJECTIVE
  Evidence is accumulating that epidermal growth factor (EGF) is a major molecule contributing to the maintenance of the integrity of the upper alimentary tract mucosa before and after injury by acid and pepsin. Patients with Zollinger-Ellison Syndrome (ZES) typically have hypersecretion of acid and pepsin; however, the concentration and rate of secretion of salivary and gastric EGF that could counteract these potentially aggressive factors are unknown. Accordingly, this study was conducted to determine whether EGF affords mucosal protection in ZES patients.
  
  
  METHODS
  The concentration and output of salivary (sEGF) and gastric epidermal growth factor (gEGF) were measured in eight patients with ZES and the results compared to those in 17 patients with nonulcer dyspepsia (NUD), serving as a control group. All patients had normal esophageal and gastric mucosa as determined by endoscopy. Total saliva was collected during 1-h parafilm- and 1-h pentagastrin/parafilm-stimulated conditions, as well as basal and pentagastrin-stimulated gastric juice. The concentration and output of EGF were determined by radioimmunoassay.
  
  
  RESULTS
  The concentration of EGF in saliva collected from ZES patients after parafilm chewing was significantly higher compared to that in NUD patients (4.61 +/- 0.59 vs 2.75 +/- 0.50 ng/ml, p < 0.05). The concentration of EGF in saliva collected after pentagastrin stimulation in ZES patients was also significantly higher than in NUD patients (4.37 +/- 0.73 vs 2.22 +/- 0.37 ng/ml, p < 0.05). Salivary EGF output during parafilm chewing in ZES and NUD were similar (68 +/- 6.4 vs 109 +/- 25.2 ng/h). Salivary EGF output after administration of pentagastrin in ZES and NUD was also similar (66 +/- 6.1 vs 132 +/- 45.4 ng/h). Basal EGF output in the gastric juice of patients with ZES was 3-fold higher than in patients with NUD (801 +/- 73 vs 271 +/- 32 ng/h, p < 0.01). Pentagastrin-stimulated EGF output was similar in both groups (705 +/- 92 vs 675 +/- 168 ng/h).
  
  
  CONCLUSIONS
  Patients with ZES have a significantly higher EGF concentration in saliva and EGF output in basal gastric juice. This elevated content of salivary and gastric EGF in ZES patients may play a protective role in preventing the development of reflux esophagitis and gastric ulcer under the impact of gastric acid and pepsin hypersecretion.
authors.affiliation: Kansas University Medical Center, Kansas City, USA.
authors.forename: J
authors.initials: J
authors.lastname: Sarosiek
authors.forename: R T
authors.initials: RT
authors.lastname: Jensen
authors.forename: P N
authors.initials: PN
authors.lastname: Maton
authors.forename: D A
authors.initials: DA
authors.lastname: Peura
authors.forename: D
authors.initials: D
authors.lastname: Harlow
authors.forename: T
authors.initials: T
authors.lastname: Feng
authors.forename: R W
authors.initials: RW
authors.lastname: McCallum
authors.forename: J R
authors.initials: JR
authors.lastname: Pisegna
mesh_terms: D000328:Adult; D004415:Dyspepsia / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000032:analysis* / Q000502:physiology; D005260:Female; D005750:Gastric Juice / Q000737:chemistry*; D005753:Gastric Mucosa / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010418:Pentagastrin / Q000494:pharmacology; D012463:Saliva / Q000737:chemistry*; D015043:Zollinger-Ellison Syndrome / Q000378:metabolism* / Q000503:physiopathology
chemical_list: D004815:Epidermal Growth Factor; D010418:Pentagastrin